Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Compugen

CGEN
Current price
2.11 USD -0.03 USD (-1.40%)
Last closed 2.14 USD
Company cgen.com
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 188 359 920 USD
Yield for 12 month +177.63 %
1Y
3Y
5Y
10Y
15Y
CGEN
21.11.2021 - 28.11.2021

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel. Address: Azrieli Center, Holon, Israel, 5885849

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

5.33 USD

P/E ratio

Dividend Yield

Current Year

+33 459 000 USD

Last Year

+7 500 000 USD

Current Quarter

+33 459 000 USD

Last Quarter

Current Year

+30 979 000 USD

Last Year

+6 525 000 USD

Current Quarter

+31 455 000 USD

Last Quarter

Key Figures CGEN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -12 516 000 USD
Operating Margin TTM 53.75 %
PE Ratio
Return On Assets TTM -7.54 %
PEG Ratio
Return On Equity TTM -26.19 %
Wall Street Target Price 5.33 USD
Revenue TTM 33 459 000 USD
Book Value 0.74 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 346.1 %
Dividend Yield
Gross Profit TTM 6 525 000 USD
Earnings per share -0.21 USD
Diluted Eps TTM -0.21 USD
Most Recent Quarter IV 2023
Quarterly Earnings Growth YOY
Profit Margin -56.05 %

Dividend Analytics CGEN

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CGEN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation CGEN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 4.5383
Price Sales TTM 6.044
Enterprise Value EBITDA -12.1322
Price Book MRQ 2.9088

Financials CGEN

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators CGEN

For 52 weeks

0.53 USD 3.03 USD
50 Day MA 2.34 USD
Shares Short Prior Month 1 948 358
200 Day MA 1.55 USD
Short Ratio 6.44
Shares Short 1 947 742
Short Percent 2.25 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

420.21 USD Microsoft Corporation -1.96 (-0.46%)
Detailed analytics

ETF funds


S

SX7EEX

14.76 EUR iShares EURO STOXX Banks 30-15 UCITS ETF (DE) +0.03 (+0.2%)
Detailed analytics

Metals


Gold

2414.65 USD Gold +37.17 (+1.56%)
Detailed analytics